Related Experiment Video

Updated: Jul 18, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

[The effectiveness of carvedilol in heart failure]

Krisztián Kárpáti1, Valentin Brodszky, Csaba Farsang

  • 1Egészség-gazdaságtani és Technológiaelemzési Munkacsoport, Közszolgálati Tanszék, Budapest.

Orvosi Hetilap
|November 23, 2006
PubMed

Insights

Carvedilol significantly reduces mortality and hospitalizations in patients with moderate to severe heart failure when used with standard therapies. This beta-blocker offers measurable benefits for patients and healthcare systems.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Third-generation beta-blocker carvedilol is recognized for its efficacy in managing hypertension.
  • Carvedilol serves as an effective adjunct to conventional heart failure treatments like diuretics and ACE inhibitors.
  • Evidence supporting carvedilol's benefits comes from randomized controlled trials and retrospective analyses.

Purpose of the Study:

  • To evaluate the efficacy of carvedilol in heart failure treatment.
  • To specifically assess carvedilol's impact on morbidity and mortality endpoints.
  • To analyze health-economic implications of carvedilol use in heart failure.

Main Methods:

  • Systematic assessment of multicenter, randomized, double-blind studies (1995-2005) from MEDLINE.
  • Inclusion criteria focused on studies with over 150 patients using carvedilol for moderate to severe heart failure.
  • Inclusion of health-economic publications from 2000-2005.

Main Results:

  • The U.S. Carvedilol Heart Failure Study showed a 65% reduction in mortality and 27% decrease in hospitalizations.
  • The COPERNICUS trial demonstrated a 35% reduction in annual mortality risk and 24% reduction in mortality or hospitalization risk.
  • The CAPRICORN study confirmed carvedilol's efficacy in reducing total and cardiovascular mortality in high-risk patients.

Conclusions:

  • Carvedilol is proven effective in reducing mortality and hospitalizations for moderate-to-severe heart failure as part of combination therapy.
  • The drug's benefits extend beyond patient outcomes to include reduced resource utilization for healthcare providers and financers.
  • Carvedilol represents a valuable therapeutic option for improving heart failure management and associated healthcare economics.
Abstract

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...